Mylan Continues to Pursue Damages and Injunction Against Sunovion's Brovana® in Ongoing Litigation

PITTSBURGH, March 2, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today commented on a ruling for partial summary judgment in its patent infringement lawsuit against Sunovion Pharmaceuticals Inc. in relation to Sunovion's Brovana^® product. The U.S. District Court for the Southern District of New York granted Sunovion's motion regarding one of Sunovion's defenses and its request to limit damages.

Mylan is disappointed in today's ruling and believes the Court erred in its decision. Mylan intends to appeal the decision. In addition, Mylan's two reexamined patents remain the subject of ongoing litigation and the company intends to continue to pursue damages and an injunction with respect to those patents.

Mylan also will continue to pursue its claims against Teva in separate litigation.

About Mylan
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Inc.